# A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va

Source: https://onco.cc/trials/nct03690388/  
OnCo record `nct03690388` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cabozantinib in thyroid cancer, run by Exelixis, active and no longer recruiting.

## Summary

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy is a phase 3 interventional study registered as NCT03690388 by Exelixis, with 187 participants enrolled, started 2018-10-05 and due to reach its primary completion in 2020-08-19. Interventions recorded: Cabozantinib, Placebo. Conditions listed: Differentiated Thyroid Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03690388
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
- Sponsor: Exelixis
- Enrolled: 187

## Sources

- ClinicalTrials.gov NCT03690388: https://clinicaltrials.gov/study/NCT03690388

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- drugs: [Cabozantinib](https://onco.cc/drugs/cabozantinib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)

---
JSON: https://onco.cc/api/v1/entities/nct03690388.json